Interferon-omega: Current status in clinical applications

  • Int Immunopharmacol. 2017 Nov;52:253-260. doi: 10.1016/j.intimp.2017.08.028.
Shi-Fang Li  1 Fu-Rong Zhao  2 Jun-Jun Shao  1 Yin-Li Xie  1 Hui-Yun Chang  3 Yong-Guang Zhang  1
Affiliations
  • 1. State Key Laboratory of Veterinary Etiological Biology, OIE/National Foot-and-Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, Gansu, China.; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, Jiangsu Province 225009, China.
  • 2. State Key Laboratory of Veterinary Etiological Biology, OIE/National Foot-and-Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, Gansu, China.; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, Jiangsu Province 225009, China.. Electronic address: [email protected].
  • 3. State Key Laboratory of Veterinary Etiological Biology, OIE/National Foot-and-Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, Gansu, China.; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, Jiangsu Province 225009, China.. Electronic address: [email protected].
Abstract

Since 1985, interferon (IFN)-ω, a type I IFN, has been identified in many Animals, but not canines and mice. It has been demonstrated to have Antiviral, anti-proliferation, and antitumor activities that are similar to those of IFN-α. To date, IFN-ω has been explored as a treatment option for some diseases or viral infections in humans and other Animals. Studies have revealed that human IFN-ω displays antitumor activities in some models of human Cancer cells and that it can be used to diagnose some diseases. While recombinant feline IFN-ω has been licensed in several countries for treating canine parvovirus, feline leukemia virus, and feline immunodeficiency virus infections, it also exhibits a certain efficacy when used to treat Other viral infections or diseases. This review examines the known biological activity of IFN-ω and its clinical applications. We expect that the information provided in this review will stimulate further studies of IFN-ω as a therapeutic agent.

Keywords
Application; Biological activity; Interferon omega; Type I IFN.
Products